Genomic and proteomic technologies will revolutionize drug discovery and development. That much is universally agreed. But, to date, pharmacological and biological databases have not been linked in a ...
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results